PubRank

Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial ID NCT02338232

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02338232

Top papers

Rank Title Journal Year PubWeight™‹?›
1 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995 24.01
2 Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003 8.68
3 Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008 7.28
4 Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2010 5.79
5 Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002 3.56
6 Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012 3.50
7 The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000 3.41
8 ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013 3.27
9 Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012 3.17
10 ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002 3.16
11 Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 2002 3.16
12 Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012 3.15
13 Leukocyte polarization in cell migration and immune interactions. EMBO J 1999 3.08
14 Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002 2.95
15 RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004 2.53
16 Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003 2.52
17 Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002 2.40
18 Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012 2.30
19 Inhibition of PMA-induced, LFA-1-dependent lymphocyte aggregation by ADP ribosylation of the small molecular weight GTP binding protein, rho. J Cell Biol 1993 2.26
20 Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011 2.24
21 Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004 2.17
22 The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol 2005 2.16
23 Identification of a tight junction-associated guanine nucleotide exchange factor that activates Rho and regulates paracellular permeability. J Cell Biol 2003 2.00
24 LFA-1-induced T cell migration on ICAM-1 involves regulation of MLCK-mediated attachment and ROCK-dependent detachment. J Cell Sci 2003 1.98
25 ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008 1.92
26 LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001 1.91
27 Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012 1.85
28 Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell Biol 2004 1.85
29 Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006 1.84
30 Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 2004 1.81
31 Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000 1.73
32 LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2003 1.67
33 Discovery and validation of graft-versus-host disease biomarkers. Blood 2012 1.67
34 Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. Blood 2013 1.62
35 ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 2009 1.61
36 ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol 1998 1.56
37 The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006 1.48
38 Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999 1.45
39 Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2009 1.42
40 Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005 1.42
41 Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002 1.39
42 Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005 1.30
43 Signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2004 1.28
44 Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003 1.25
45 Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 2006 1.22
46 ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest 2007 1.22
47 Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 2003 1.20
48 Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006 1.13
49 Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2001 1.10
50 Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One 2008 1.08
51 Human microbiota characterization in the course of renal transplantation. Am J Transplant 2013 1.02
52 Novel treatment concepts for graft-versus-host disease. Blood 2011 1.02
53 Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 2013 1.01
54 HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 2010 1.00
55 Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004 1.00
56 Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 2010 0.98
57 Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008 0.97
58 Bench-to-bedside review: Clinical experience with the endotoxin activity assay. Crit Care 2012 0.95
59 Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012 0.95
60 Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2007 0.95
61 The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011 0.94
62 Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes. Bone Marrow Transplant 2010 0.94
63 Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000 0.94
64 Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Jpn J Ophthalmol 2008 0.93
65 Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005 0.92
66 Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2011 0.92
67 Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes. FEBS Lett 2003 0.92
68 Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp Hematol 2012 0.92
69 Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 2010 0.91
70 Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 2007 0.90
71 Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008 0.90
72 The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013 0.89
73 Safety of telmisartan in patients with arterial hypertension : an open-label observational study. Drug Saf 2004 0.89
74 Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008 0.88
75 Is there a 'gut-brain-skin axis'? Exp Dermatol 2010 0.87
76 CAMs and Rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on "VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration". Am J Physiol Cell Physiol 2003 0.87
77 Graft-versus-host disease. Panminerva Med 2010 0.86
78 Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 0.86
79 Telmisartan: a review of its use in hypertension. Drugs 2001 0.86
80 Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant 2011 0.86
81 Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PLoS One 2014 0.86
82 Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 2007 0.86
83 Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis 2014 0.85
84 Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001 0.85
85 Impact of endotoxin measured by an endotoxin activity assay during liver transplantation. J Surg Res 2012 0.84
86 Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014 0.84
87 Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension 2007 0.83
88 The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008 0.83
89 The role of bacteria and pattern recognition receptors in GVHD. Int J Inflam 2010 0.83
90 Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2008 0.82
91 Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One 2013 0.82
92 Rho-kinase and contractile apparatus proteins in murine airway hyperresponsiveness. Exp Toxicol Pathol 2008 0.82
93 Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ J 2006 0.81
94 Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012 0.81
95 A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. Blood 2013 0.81
96 Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model. J Immunol 2012 0.80
97 High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension 2011 0.80
98 Rho kinase signalling mediates radiation-induced inflammation and intestinal barrier dysfunction. Br J Surg 2010 0.80
99 Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol 2004 0.79
100 Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate Immun 2014 0.78
Next 100